Hepatocellular carcinoma: genes and variants
Explore variant evidence for Hepatocellular carcinoma across 19 analyzed proteins (CTNNB1, MET, TP53, TERT, APC and 14 more). Linked ClinVar records include 6 pathogenic or likely pathogenic variants, 30 variants of uncertain significance and 24 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-04. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Hepatocellular carcinoma
CTNNB1: Catenin beta-1
It links cadherins to the cytoskeleton at adherens junctions and, when stabilized by Wnt signaling, enters the nucleus to regulate transcription. Activating somatic variants drive many cancers, while germline loss-of-function variants cause CTNNB1 neurodevelopmental disorder.
3 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CTNNB1 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
MET: Hepatocyte growth factor receptor
Hepatocyte-growth-factor signaling through this pathway promotes cell survival, proliferation, motility, and invasive growth during development and tissue repair. Exon 14 skipping, amplification, activating mutations, or fusions can drive cancer and create actionable therapeutic dependencies.
1 ClinVar pathogenic / likely pathogenic and 33 uncertain variants in MET have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
TP53: Cellular tumor antigen p53
It coordinates transcriptional responses to DNA damage and other cellular stresses, promoting cell-cycle arrest, senescence, DNA repair, or apoptosis when appropriate. Loss of this tumor-suppressive control is one of the most common events in cancer, while germline pathogenic variants cause Li-Fraumeni syndrome.
1 ClinVar pathogenic / likely pathogenic and 2 uncertain variants in TP53 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
TERT: Telomerase reverse transcriptase
It extends telomeric DNA using an internal RNA template and helps counter progressive chromosome-end shortening in stem and proliferative cells. Loss-of-function variants cause telomere-biology disorders, while promoter activation and increased activity support unlimited proliferation in many cancers.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TERT have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
APC: Adenomatous polyposis coli protein
A tumor-suppressor protein that promotes the removal of beta-catenin and helps keep Wnt signaling under control. It also organizes microtubules and actin in the cell, and inherited APC disruption is strongly associated with familial adenomatous polyposis and colorectal tumor risk.
0 ClinVar pathogenic / likely pathogenic and 13 uncertain variants in APC have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Its p110-alpha catalytic activity generates PIP3 and activates AKT-dependent growth, survival, and metabolic signaling downstream of many receptors. Activating variants are frequent cancer drivers and, when present mosaically during development, can cause PIK3CA-related overgrowth spectrum.
0 ClinVar pathogenic / likely pathogenic and 5 uncertain variants in PIK3CA have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
ARID1A: AT-rich interactive domain-containing protein 1A
It helps BAF chromatin-remodeling complexes open or reposition nucleosomes at regulatory regions and thereby control lineage-specific transcription. Somatic loss is frequent in several cancers, while germline haploinsufficiency can cause Coffin-Siris syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ARID1A have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
ARID2: AT-rich interactive domain-containing protein 2
It contributes DNA targeting and regulatory specificity to PBAF chromatin-remodeling complexes. Somatic loss-of-function alterations occur in melanoma, liver cancer, and other tumors, while germline variants can cause a Coffin-Siris-spectrum neurodevelopmental disorder.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ARID2 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in BRAF have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
CD274: Programmed cell death 1 ligand 1
By engaging PD-1, it suppresses activated T cells by engaging PD-1 and thereby limits immune-mediated tissue damage. Many cancers exploit high PD-L1 expression to evade immune attack, making the PD-1/PD-L1 axis a central target of immune-checkpoint therapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CD274 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
CDKN2A: Tumor suppressor ARF
The ARF product of CDKN2A is a tumor-suppressor protein that binds MDM2 and helps preserve p53 activity. By promoting cell-cycle arrest and apoptosis, it provides an important barrier to uncontrolled cell growth from within the nucleolus.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CDKN2A have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
CTLA4: Cytotoxic T-lymphocyte protein 4
It restrains T-cell activation by competing with CD28 for CD80 and CD86 and by delivering inhibitory signals after immune activation. Haploinsufficiency causes immune dysregulation with autoimmunity and lymphoproliferation, while therapeutic blockade enhances antitumor immunity.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CTLA4 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
FLT3: Receptor-type tyrosine-protein kinase FLT3
Its signaling supports survival and expansion of early hematopoietic progenitors. Internal tandem duplications and kinase-domain mutations produce constitutive activity in acute myeloid leukemia and are important prognostic markers and therapeutic targets.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FLT3 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
KIT: Mast/stem cell growth factor receptor Kit
Stem-cell-factor signaling through this pathway supports hematopoietic progenitors, mast cells, melanocytes, and germ cells. Activating variants drive gastrointestinal stromal tumors, systemic mastocytosis, and other malignancies, whereas loss-of-function variants can cause piebaldism.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in KIT have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
NFE2L2: Nuclear factor erythroid 2-related factor 2
It activates antioxidant, detoxification, and metabolic genes when released from KEAP1-mediated degradation. Somatic activating variants can lock cancer cells into a persistent stress-resistant state and promote therapy resistance.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NFE2L2 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
PDGFRB: Platelet-derived growth factor receptor beta
Its signaling supports pericytes, vascular smooth-muscle cells, and other mesenchymal lineages during growth and tissue repair. Oncogenic fusions drive myeloid neoplasms, while germline activating or loss-of-function variants can cause developmental and vascular disorders.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDGFRB have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
RB1: Retinoblastoma-associated protein
It restrains E2F-dependent transcription and prevents inappropriate G1-to-S cell-cycle progression until proliferative signals are appropriate. Loss of function is a fundamental cancer-driving event, while germline pathogenic variants cause hereditary retinoblastoma and increase risk of additional tumors.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RB1 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
RET: Proto-oncogene tyrosine-protein kinase receptor Ret
Its activation by GDNF-family ligands guides development of the enteric nervous system, kidney, and other tissues. Activating variants cause multiple endocrine neoplasia type 2 and can drive cancer, whereas loss-of-function variants are an important cause of Hirschsprung disease.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in RET have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
TSC2: Tuberin
Together with TSC1, it inactivates RHEB and restrains mTORC1 when growth conditions are unfavorable. Loss-of-function variants cause tuberous sclerosis complex with hamartomas and tumors affecting the brain, kidneys, skin, heart, lungs, and other organs.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in TSC2 have source records linked to Hepatocellular carcinoma. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): AQP7, CASP8, F13B, GNAI1, HLA-DPA1 and JMJD4.
ClinVar pathogenic and likely pathogenic variants linked to Hepatocellular carcinoma
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| TP53 R273G | 273 | DNA binding | Pathogenic / likely pathogenic (★★) |
| CTNNB1 T41A | 41 | Pathogenic / likely pathogenic (★★) | |
| MET H1094R | 1094 | Protein kinase | Pathogenic / likely pathogenic (★★) |
| CTNNB1 S45F | 45 | Pathogenic / likely pathogenic | |
| CTNNB1 S45P | 45 | Pathogenic / likely pathogenic | |
| TERT E668D | 668 | Reverse transcriptase | Pathogenic / likely pathogenic |
Same protein, different disease
- Pilomatrixoma also has ClinVar records linked to CTNNB1 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (8 pathogenic / likely pathogenic).
- Severe intellectual disability-progressive spastic diplegia syndrome also has ClinVar records linked to CTNNB1 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (5 pathogenic / likely pathogenic).
- Medulloblastoma also has ClinVar records linked to CTNNB1 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (4 pathogenic / likely pathogenic).
- Renal cell carcinoma also has ClinVar records linked to MET variants; they fall mostly in different places as the Hepatocellular carcinoma variants (4 pathogenic / likely pathogenic).
- Dyskeratosis congenita also has ClinVar records linked to TERT variants; they fall mostly in different places as the Hepatocellular carcinoma variants (23 pathogenic / likely pathogenic).
- Idiopathic pulmonary fibrosis also has ClinVar records linked to TERT variants; they fall mostly in different places as the Hepatocellular carcinoma variants (13 pathogenic / likely pathogenic).
- Pulmonary fibrosis and/or bone marrow failure, Telomere-related also has ClinVar records linked to TERT variants; they fall mostly in different places as the Hepatocellular carcinoma variants (13 pathogenic / likely pathogenic).
- Li-Fraumeni syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (188 pathogenic / likely pathogenic).
- Adrenocortical carcinoma, hereditary also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (23 pathogenic / likely pathogenic).
- Acute myeloid leukemia also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (6 pathogenic / likely pathogenic).
- Hereditary breast ovarian cancer syndrome also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (6 pathogenic / likely pathogenic).
- Hereditary breast cancer also has ClinVar records linked to TP53 variants; they fall mostly in different places as the Hepatocellular carcinoma variants (5 pathogenic / likely pathogenic).
Diseases related to Hepatocellular carcinoma
- Colorectal cancer, also linked to APC, ARID1A, BRAF, CTNNB1 and 6 more
- Non-small cell lung carcinoma, also linked to BRAF, CD274, CDKN2A, CTLA4 and 5 more
- Urinary bladder cancer, also linked to ARID1A, CDKN2A, CTNNB1, PIK3CA and 3 more
- Renal cell carcinoma, also linked to BRAF, CTLA4, FLT3, KIT and 3 more
- Ovarian cancer, also linked to APC, CTNNB1, KIT, PIK3CA and 2 more
- Lung adenocarcinoma, also linked to ARID1A, BRAF, CDKN2A, RB1 and 2 more
- Acute myeloid leukemia, also linked to FLT3, KIT, PDGFRB, TERT and 1 more
- Head and neck squamous cell carcinoma, also linked to CD274, CDKN2A, NFE2L2, PIK3CA and 1 more
- Gastrointestinal stromal tumor, also linked to FLT3, KIT, PDGFRB and RET
- Colon carcinoma, also linked to APC, BRAF, CTNNB1 and PIK3CA
- Lung cancer, also linked to BRAF, CD274, NFE2L2 and PIK3CA
- Melanoma, also linked to ARID2, BRAF, CDKN2A and CTLA4
Frequently asked questions
Which genes have records linked to Hepatocellular carcinoma?
This view contains 19 analyzed proteins: CTNNB1, MET, TP53, TERT, APC and 14 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 6 pathogenic or likely pathogenic variants, 30 variants of uncertain significance and 24 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 74 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center